Jamal Maatouk, MD
Medical Oncology · Kingsport, TNNPI 1205016060
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $32,695 of the $47,432 with a category attached, or 68.9%. Incyte Corporation accounts for 94.2% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $17,073 and has fallen 89.1% since, to $1,852 in 2025.
Across 171 payments — averaging $277.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$45K
- Novartis$514
- Covis Pharma GmbH$200
- Daiichi Sankyo Inc.$182
- Gilead$148
- Lilly USA, LLC$125
- plus $2K from 34 others
What the payments were for
- Consulting fees$6,86014%
- Speaking & faculty fees$32,69569%
- Travel & lodging$3,8358%
- Food & beverage$3,6358%
- Education$4071%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 56 | $44,682 |
| Novartis | 27 | $514 |
| Covis Pharma GmbH | 1 | $200 |
| Daiichi Sankyo Inc. | 8 | $182 |
| Gilead(2 entities) | 6 | $148 |
| Lilly USA, LLC | 2 | $125 |
| Regeneron Healthcare Solutions, Inc. | 4 | $114 |
| Intera Oncology, Inc | 1 | $112 |
| Merck | 6 | $107 |
| Eisai Inc. | 5 | $105 |
| GSK | 5 | $103 |
| AstraZeneca(2 entities) | 3 | $88 |
| Johnson & Johnson(2 entities) | 4 | $80 |
| Taiho Oncology, Inc. | 3 | $73 |
| Pharmacosmos Therapeutics Inc. | 3 | $64 |
| Exelixis Inc. | 3 | $58 |
| Puma Biotechnology, Inc. | 3 | $55 |
| Pfizer | 3 | $53 |
| Seagen Inc. | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $44 |
| Beone Medicines USA, Inc. | 2 | $41 |
| Array Biopharma Inc | 2 | $37 |
| AbbVie | 2 | $35 |
| Bristol Myers Squibb | 1 | $35 |
| Astellas Pharma US Inc | 2 | $31 |
| Tersera Therapeutics LLC | 1 | $27 |
| Spectrum Pharmaceuticals Inc. | 1 | $26 |
| Beigene USA, Inc. | 1 | $24 |
| Iovance Biotherapeutics, Inc. | 1 | $24 |
| Karyopharm Therapeutics Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $22 |
| Boehringer Ingelheim | 1 | $22 |
| Mirati Therapeutics, Inc. | 1 | $21 |
| Geron Corporation | 1 | $19 |
| Rigel Pharmaceuticals, Inc. | 1 | $18 |
| EMD Serono, Inc. | 1 | $16 |
| Bayer | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| ADC Therapeutics America, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$47,432 in reported general payments places this provider in the 80th percentile of 101 medical oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 19 | $11,145 |
| Exemestane | 13 | $3,097 |
| Tamoxifen Citrate | 52 | $2,376 |
| Anastrozole | 102 | $2,186 |
| Potassium Chloride | 36 | $700 |
| Ondansetron Hcl | 54 | $685 |
| Dexamethasone | 53 | $559 |
| Prochlorperazine Maleate | 52 | $535 |
| Letrozole | 30 | $505 |
| Hydroxyurea | 14 | $318 |
| Famotidine | 14 | $222 |
| Escitalopram Oxalate | 12 | $125 |
| Allopurinol | 12 | $26 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $80 | $11,14519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 medical oncology providers in Tennessee.
Other medical oncology in Kingsport
- Kanishka ChakrabortyKingsport$5K
- William PaoNashville$838K
- Gregory VidalGermantown$360K
- Dana ThompsonNashville$339K
- Robert RamirezNashville$321K
- Mace RothenbergNashville$318K
- Melissa JohnsonNashville$290K
- Gina VaccaroCookeville$248K
- Jason ChandlerGermantown$234K
- Cathy EngNashville$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.